The following information is as of March 1, 2022.

The number of shares in issue is 101,286,992. The percentage of shares not in public hands is 15%. The list below is all disclosed holdings of 3% or larger.

Rank Shareholder / Registered holder Shares %
1 Casdin Capital 13,971,334 13.81%
2 Baron Capital Management 5,065,171 5.00%
3 Sofinnova Crossover I SLP 4,976,496 4.91%
4 BlackRock Institutional Trust 4,618,105 4.56%
7 Life Tech Sarl (Luxembourg)* 4,053,531 4.01%
5 D1 Capital Partners L.P. 3,510,000 3.47%
6 The Vanguard Group 3,157,690 3.12%

*The Vitruvian Investment Partnership III is managed by Vitruvian Partners LLP (the latter authorized and regulated by the UK Financial Conduct Authority) and is deemed to be the ultimate beneficial owner of Life Tech S.à r.l.

Rights of shareholders

The rights of shareholders are governed by UK law.

Restrictions in transfer of ordinary shares

There are no restrictions on the transfer of the company’s ordinary shares.

UK city code on takeover and mergers

The Company is not subject to the Takeover Code because its registered office and its place of central management and control are outside the UK, the Channel Islands and the Isle of Man. As a result, certain protections that are afforded to Shareholders under the UK Takeover Code, for example in relation to a takeover of a company or certain stakebuilding activities by shareholders, do not apply to the Company. Although the Company has inserted certain provisions into the Certificate of Incorporation which adopt similar procedures to the UK Takeover Code in the event of any party (or parties acting in concert) obtaining 30 per cent, or more of the voting rights attaching to the issued Common Stock, there is no assurance that the courts of the State of Delaware will uphold or allow the enforcement of these provisions. Further details relating to these provisions are set out in paragraph 15 of Part 5 of the Company’s Admission document.

Other exchanges and trading platforms

The securities of the Company are traded on the AIM market operated by the London Stock Exchange plc. MaxCyte is also traded on the Nasdaq Global Select Market and is subject to the regulations of the U.S. Securities and Exchange Commission. SEC filings can be found here.